181 related articles for article (PubMed ID: 29987398)
1. A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts.
He H; Liu C; Wu Y; Zhang X; Fan J; Cao Y
Pharm Res; 2018 Jul; 35(9):174. PubMed ID: 29987398
[TBL] [Abstract][Full Text] [Related]
2. Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.
Vaidya TR; Mody H; Franco YL; Brown A; Ait-Oudhia S
AAPS J; 2021 Jan; 23(1):18. PubMed ID: 33404976
[TBL] [Abstract][Full Text] [Related]
3. Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart.
Sun XP; Wan LL; Yang QJ; Huo Y; Han YL; Guo C
Arch Pharm Res; 2017 Jul; 40(7):875-883. PubMed ID: 28315259
[TBL] [Abstract][Full Text] [Related]
4. Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling.
Lee JB; Zhou S; Chiang M; Zang X; Kim TH; Kagan L
Biopharm Drug Dispos; 2020 Apr; 41(4-5):192-205. PubMed ID: 32342986
[TBL] [Abstract][Full Text] [Related]
5. Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling.
Verheijen M; Schrooders Y; Gmuender H; Nudischer R; Clayton O; Hynes J; Niederer S; Cordes H; Kuepfer L; Kleinjans J; Caiment F
Toxicol Lett; 2018 Sep; 294():184-192. PubMed ID: 29803840
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
7. Liposomal co-delivered oleanolic acid attenuates doxorubicin-induced multi-organ toxicity in hepatocellular carcinoma.
Sarfraz M; Afzal A; Raza SM; Bashir S; Madni A; Khan MW; Ma X; Xiang G
Oncotarget; 2017 Jul; 8(29):47136-47153. PubMed ID: 28525367
[TBL] [Abstract][Full Text] [Related]
8. Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity.
Galal A; El-Bakly WM; Al Haleem EN; El-Demerdash E
Cancer Chemother Pharmacol; 2016 Feb; 77(2):309-22. PubMed ID: 26676227
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity.
Mitra MS; Donthamsetty S; White B; Latendresse JR; Mehendale HM
Toxicol Appl Pharmacol; 2007 Nov; 225(1):90-101. PubMed ID: 17904602
[TBL] [Abstract][Full Text] [Related]
10. Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis.
Abdel-Daim MM; Kilany OE; Khalifa HA; Ahmed AAM
Cancer Chemother Pharmacol; 2017 Oct; 80(4):745-753. PubMed ID: 28785995
[TBL] [Abstract][Full Text] [Related]
11. A short-time model to study relevant indices of cardiotoxicity of doxorubicin in the rat.
Hole LD; Larsen TH; Fossan KO; Limé F; Schjøtt J
Toxicol Mech Methods; 2013 Jul; 23(6):412-8. PubMed ID: 23379389
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy.
Zhang QL; Yang JJ; Zhang HS
Biomed Pharmacother; 2019 Jan; 109():71-83. PubMed ID: 30396094
[TBL] [Abstract][Full Text] [Related]
13. Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage.
Nitiss KC; Nitiss JL
Clin Cancer Res; 2014 Sep; 20(18):4737-9. PubMed ID: 24916696
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs as potential biomarkers for doxorubicin-induced cardiotoxicity.
Holmgren G; Synnergren J; Andersson CX; Lindahl A; Sartipy P
Toxicol In Vitro; 2016 Aug; 34():26-34. PubMed ID: 27033315
[TBL] [Abstract][Full Text] [Related]
15. Short-term doxorubicin cardiotoxic effects: involvement of cardiac Thyrotropin Releasing Hormone system.
Peres Diaz LS; Schuman ML; Aisicovich M; Toblli JE; Pirola CJ; Landa MS; García SI
Life Sci; 2020 Nov; 261():118346. PubMed ID: 32853656
[TBL] [Abstract][Full Text] [Related]
16. Examination of the effects of thiamine and thiamine pyrophosphate on Doxorubicin-induced experimental cardiotoxicity.
Polat B; Suleyman H; Sener E; Akcay F
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):221-9. PubMed ID: 25316705
[TBL] [Abstract][Full Text] [Related]
17. A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition.
Dubbelboer IR; Lilienberg E; Sjögren E; Lennernäs H
Mol Pharm; 2017 Mar; 14(3):686-698. PubMed ID: 28182434
[TBL] [Abstract][Full Text] [Related]
18. Means of evaluation and protection from doxorubicin-induced cardiotoxicity and hepatotoxicity in rats.
Salouege I; Ben Ali R; Ben Saïd D; Elkadri N; Kourda N; Lakhal M; Klouz A
J Cancer Res Ther; 2014; 10(2):274-8. PubMed ID: 25022377
[TBL] [Abstract][Full Text] [Related]
19. Implications of chronic moderate protein-deficiency malnutrition on doxorubicin pharmacokinetics and cardiotoxicity in early post-weaning stage.
Garg M; Gandhi K; Gera P; Jadhav SM; Mohanty B; Gurjar M; Sandupatla B; Gala R; Chaudhari P; Prasad M; Chinnaswamy G; Gota V
Life Sci; 2024 Aug; 350():122765. PubMed ID: 38830506
[TBL] [Abstract][Full Text] [Related]
20. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
